Thousand Oaks Biopharmaceuticals
Founded Year
2017Stage
Series C - II | AliveTotal Raised
$404.73MLast Raised
$235.37M | 1 yr agoAbout Thousand Oaks Biopharmaceuticals
Thousand Oaks Biopharmaceuticals is an integrated CMC organization which enables its partners to provide affordable and accessible biologics for patients worldwide. The company provides high quality raw material, consumables, novel equipment, technical services and consultation, integrated CDMO services including cell line development from DNA sequences, process, analytical and customized cell cultural medium development, early, late phase clinical material supply and commercial manufacturing, bioanalytical services and regulatory filings, to speed biologics development from bench through clinic to market.
Missing: Thousand Oaks Biopharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Thousand Oaks Biopharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Thousand Oaks Biopharmaceuticals Patents
Thousand Oaks Biopharmaceuticals has filed 16 patents.
The 3 most popular patent topics include:
- Graphical projections
- House types
- Cuttlefish

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
7/10/2019 | 4/5/2022 | Bags, Postal system, Postal services, House types, Cycling equipment | Grant |
Application Date | 7/10/2019 |
---|---|
Grant Date | 4/5/2022 |
Title | |
Related Topics | Bags, Postal system, Postal services, House types, Cycling equipment |
Status | Grant |
Latest Thousand Oaks Biopharmaceuticals News
Mar 10, 2021
Source: National Cancer Institute/Unsplash March 10, 2021 Thousand Oaks Biopharmaceuticals has raised over 400 million yuan ($61 million) in its Series C round of financing co-led by China State-Owned Capital Venture Investment Fund and GL Ventures, while Taipei-based Influenxio has garnered $2 million from DCM Ventures. GL co-leads $61m funding in Thousand Oaks China’s Thousand Oaks Biopharmaceuticals, Inc has bagged over 400 million yuan ($61 million) in its Series C round of financing co-led by China State-Owned Capital Venture Investment Fund and Asia’s PE firm Hillhouse Capital’s venture unit GL Ventures. Alternative assets investment manager CDH Investments, China-US Green Fund, and Sany Group’s PE arm Sany Foundation have joined as new investors, while return backers namely CICC Capital, CITIC Securities’ investment arm Goldstone Fosun Group’s sub-fund re-upped in the round, per a company statement on Wednesday. Investment bank CEE Capital facilitated the transaction. In January this year, Thousand Oaks had tied-up with Korea’s WSG Group to set up a bioprocess solution JV to speed up the Korean biopharma industry by supplying serum-free cell culture media. Before the latest round, Thousand Oaks had closed 450 million yuan ($69 million) Series B round funding from CICC Capital, GL Ventures, China Construction Bank’s CCB International and other investors in July 2020. Taiwan’s Influenxio bags $2m Influenxio, a Taipei-headquartered leading social marketing platform for small businesses, has secured $2 million in its pre-Series A funding led by DCM Ventures. The three-year-old Influenxio has so far raised over $3 million in funding. Influenxio plans to deploy the proceeds towards talent recruitment and product development. It will also support the revamp of its Japan-based platform and expand to overseas markets. Influenxio helps small-to-medium enterprises in Taiwan and Japan to conduct marketing campaigns for audience engagements. Sign up for our newsletter - The Daily Brief Opt out of receiving The Daily Brief in your inbox everyday REGISTER 2You have one free story left this month.You have 2 free stories left this month.This is your last free story of the month. Register to continue reading our free content. × We will never share your information with third parties. If you don’t already have an account click the button below to create your account. Join DealstreetAsia's premium subscription service Unlock your competitive advantage in a rapidly evolving landscape. Our packages come with exclusive access to archive content, data, discount on summit tickets & more. Be a part of our growing community now. Singapore Reporter/s In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must. Following vacancies can be applied for (only in Singapore). Following vacancies can be applied for (only in Singapore). A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion. A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia. Singapore Reporter/s In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must. Following vacancies can be applied for (only in Singapore). Following vacancies can be applied for (only in Singapore). A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion. A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.
Thousand Oaks Biopharmaceuticals Frequently Asked Questions (FAQ)
When was Thousand Oaks Biopharmaceuticals founded?
Thousand Oaks Biopharmaceuticals was founded in 2017.
Where is Thousand Oaks Biopharmaceuticals's headquarters?
Thousand Oaks Biopharmaceuticals's headquarters is located at Building B1, Dongtinghu Road No.100, Nantong.
What is Thousand Oaks Biopharmaceuticals's latest funding round?
Thousand Oaks Biopharmaceuticals's latest funding round is Series C - II.
How much did Thousand Oaks Biopharmaceuticals raise?
Thousand Oaks Biopharmaceuticals raised a total of $404.73M.
Who are the investors of Thousand Oaks Biopharmaceuticals?
Investors of Thousand Oaks Biopharmaceuticals include GoldStone Investment, CDH Investments, China Capital Investment Group, Hillhouse Capital Management, HighLight Capital and 15 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.